ArticleReviews in cardiovascular medicine2025
Incremental Prognostic Value of Cystatin C-Based Estimated Glomerular Filtration Rate in Patients With Acute Coronary Syndrome.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which incorporates both creatinine and cystatin C, provides enhanced estimation of glomerular filtration rate (eGFR) compared to creatinine-only equations. This study aimed to explore the incremental prognostic value of eGFR estimates in patients with acute coronary syndrome (ACS). Method: This retrospective analysis evaluated 1400 ACS patients undergoing a percutaneous coronary intervention (PCI). The primary endpoint was defined as major adverse cardiovascular events (MACEs), a composite of all-cause death and nonfatal myocardial infarction (MI). The eGFR values were calculated using three equations: one based solely on serum creatinine (eGFR Results: Over a median follow-up of 31.03 (27.34, 35.06) months, 135 (9.6%) patients experienced MACEs, including 99 (7.1%) deaths and 41 (2.9%) MIs. Lower eGFR values correlated with higher MACEs and the risk of death. Incorporating eGFR Conclusion: The eGFR based on the 2021 CKD-EPI equation using both creatinine and cystatin C significantly improves risk prediction and reclassification in ACS patients compared with a creatinine-based equation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.